FAQ

ABT-089

Known as: A-87089.0, ABT 089, ABYT 089 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2014
024619972014

Related topics

Related topics

1 relation

Broader (1)

pozanicline

Related mentions per year

Related mentions per year

1997-2015
1990200020102020
ABT-089
pozanicline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.
Nicotine withdrawal produces cognitive deficits that can predict relapse. Amelioration of these cognitive deficits emerges as a… (More)
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
Is this relevant?
2014
2014
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Levodopa-induced dyskinesias (LIDs) are a serious complication of levodopa therapy for Parkinson's disease for which there is… (More)
Is this relevant?
2011
2011
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
OBJECTIVE To assess the safety and efficacy of ABT-089, a novel α(4)β(2) neuronal nicotinic receptor partial agonist, vs. placebo… (More)
Is this relevant?
2011
2011
Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled…
α4β2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2009
2009
Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.
Numerous pharmaceutical efforts have targeted neuronal nicotinic receptors (nAChRs) for amelioration of cognitive deficits. While… (More)
Is this relevant?
2006
2006
ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
BACKGROUND This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for… (More)
Is this relevant?
1998
1998
Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys
 Increased distractibility is associated with both Alzheimer’s disease and attention deficit disorder. The present study examined… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
Accumulating preclinical and clinical evidence data suggests that compounds that selectively activate neuronal nicotinic… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
1997
1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing…
2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine, ABT-089 (S-4), a member of the 3-pyridyl ether class of nicotinic acetylcholine… (More)
Is this relevant?